Trinity Legacy Partners LLC Lowers Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Trinity Legacy Partners LLC cut its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 18.8% during the 4th quarter, HoldingsChannel reports. The firm owned 517 shares of the pharmaceutical company’s stock after selling 120 shares during the period. Trinity Legacy Partners LLC’s holdings in Vertex Pharmaceuticals were worth $208,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Bray Capital Advisors boosted its position in shares of Vertex Pharmaceuticals by 15.9% during the fourth quarter. Bray Capital Advisors now owns 4,554 shares of the pharmaceutical company’s stock valued at $1,834,000 after buying an additional 624 shares during the last quarter. Mattern Capital Management LLC boosted its holdings in shares of Vertex Pharmaceuticals by 8.3% during the 4th quarter. Mattern Capital Management LLC now owns 1,873 shares of the pharmaceutical company’s stock valued at $754,000 after acquiring an additional 144 shares during the last quarter. Zullo Investment Group Inc. grew its stake in shares of Vertex Pharmaceuticals by 6.6% in the fourth quarter. Zullo Investment Group Inc. now owns 802 shares of the pharmaceutical company’s stock worth $323,000 after acquiring an additional 50 shares during the period. Cumberland Partners Ltd raised its holdings in shares of Vertex Pharmaceuticals by 9.6% during the fourth quarter. Cumberland Partners Ltd now owns 47,326 shares of the pharmaceutical company’s stock valued at $19,058,000 after purchasing an additional 4,126 shares during the last quarter. Finally, Fagan Associates Inc. boosted its holdings in Vertex Pharmaceuticals by 0.4% in the fourth quarter. Fagan Associates Inc. now owns 26,518 shares of the pharmaceutical company’s stock worth $10,679,000 after purchasing an additional 93 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total transaction of $111,034.64. Following the completion of the transaction, the executive vice president now directly owns 67,695 shares of the company’s stock, valued at $30,805,286.70. The trade was a 0.36 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Up 1.8 %

Shares of VRTX opened at $480.33 on Friday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The company’s fifty day moving average is $435.64 and its two-hundred day moving average is $460.65.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Equities analysts predict that Vertex Pharmaceuticals Incorporated will post 15.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Canaccord Genuity Group upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and lifted their price target for the stock from $408.00 to $424.00 in a research note on Tuesday, February 11th. BMO Capital Markets decreased their price objective on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating on the stock in a research report on Friday, December 20th. William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. Morgan Stanley lifted their target price on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 11th. Finally, Scotiabank raised their price target on Vertex Pharmaceuticals from $433.00 to $450.00 and gave the company a “sector perform” rating in a report on Tuesday, February 11th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $505.61.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.